ADVANCED THERAPIES XCHANGE
April 3, 2023
Welcome to hubXchange’s Advanced Therapies Xchange 2023, East Coast, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in cell and gene therapeutics.
Discussion topics will cover Cell Tx Development, Gene Tx Development, C&G Tx Bioprocessing and C&G Tx Manufacturing.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Venue Details: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801
Cell Tx Development
Opening Address & Keynote Presentation
Enhancing CAR-T cell efficacy
Alternatives to autologous- allogenic and in vivo cell therapies
4:20 – 5:20pm
The Promise and Challenges of PSC-CAR-NK Cell Therapy
- Promise: CAR-NK cells from pluripotent stem cells (PSC) will potentially provide an inexhaustible cell source of allogenic/off-the-shelf therapeutics for all patients worldwide.
- Challenges: Tumorigenic potential from undifferentiated PSCs, CMC and manufacture; and limited sustainability in vivo.
- Discussion points: Differentiation process and QA/QC; scalable manufacture; and gene editing strategy
President and CEO, HebeCell
John Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and pluripotent stem cell (PSC)-CAR-NK cells for the treatment of human diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics for 11 years. John has more than 20 years of experience in stem cell biology and regenerative medicine as well as >10 year experiences in cancer research. John is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, John’s patent application and citation ranked No. 7 and No. 5, respectively.